NYSEAMERICAN:PFNX - Pfenex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.40 -0.11 (-2.44 %)
(As of 11/20/2018 04:00 PM ET)
Previous Close$4.51
Today's Range$4.38 - $4.58
52-Week Range$2.07 - $8.42
Volume27,000 shs
Average Volume151,278 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Pfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study. It develops PF529, a biosimilar candidate to Neulasta; PF530, a biosimilar candidate to Betaseron; and hematology/oncology products, including PF743 and PF745. The company has collaboration agreement with Jazz Pharmaceuticals Ireland Limited and Hospira, Inc., as well as a contract agreement with The National Institute of Allergy and Infectious Diseases. Pfenex Inc. is headquartered in San Diego, California.

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:PFNX
Previous SymbolNYSEMKT:PFNX
CUSIPN/A
Phone+1-858-3524400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares31,460,000
Market Cap$0.00
OptionableOptionable

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEAMERICAN:PFNX) announced its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.10. The biotechnology company earned $3.57 million during the quarter, compared to analysts' expectations of $6.30 million. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Pfenex.

What price target have analysts set for PFNX?

2 Wall Street analysts have issued 1-year target prices for Pfenex's stock. Their predictions range from $8.00 to $8.00. On average, they anticipate Pfenex's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 81.8% from the stock's current price. View Analyst Price Targets for Pfenex.

What is the consensus analysts' recommendation for Pfenex?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfenex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pfenex.

Has Pfenex been receiving favorable news coverage?

Media coverage about PFNX stock has trended somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Pfenex earned a news impact score of 0.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the company's share price in the next several days.

Are investors shorting Pfenex?

Pfenex saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 841,848 shares, a drop of 4.7% from the October 15th total of 883,519 shares. Based on an average trading volume of 65,402 shares, the days-to-cover ratio is currently 12.9 days. Currently, 2.7% of the company's shares are short sold. View Pfenex's Current Options Chain.

Who are some of Pfenex's key competitors?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 46)
  • Ms. Patricia Lady C.M.A., CPA, M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 60)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 50)
  • Dr. Hubert C. Chen, Advisor (Age 49)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 54)

Who are Pfenex's major shareholders?

Pfenex's stock is owned by many different of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (13.77%), Primecap Management Co. CA (10.85%), Blair William & Co. IL (6.33%), BlackRock Inc. (4.93%), Renaissance Technologies LLC (3.83%) and Sanders Morris Harris LLC (2.75%). Company insiders that own Pfenex stock include Evert B Schimmelpennink, Jason Grenfell-Gardner, Patricia Lady, Phillip M Schneider, Robin Campbell and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex.

Which institutional investors are selling Pfenex stock?

PFNX stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Alambic Investment Management L.P., Sanders Morris Harris LLC, TIAA CREF Investment Management LLC and C WorldWide Group Holding A S. View Insider Buying and Selling for Pfenex.

Which institutional investors are buying Pfenex stock?

PFNX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Primecap Management Co. CA, JPMorgan Chase & Co., JPMorgan Chase & Co. and Blair William & Co. IL. Company insiders that have bought Pfenex stock in the last two years include Evert B Schimmelpennink, Jason Grenfell-Gardner, Phillip M Schneider and Robin Campbell. View Insider Buying and Selling for Pfenex.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $4.40.

What is Pfenex's official website?

The official website for Pfenex is http://www.pfenex.com/.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (NYSEAMERICAN PFNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  282
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel